Solstice Oncology, the partner of Hong Kong-listed Harbour BioMed, launched with a US$225 million Series A led by RA Capital Management alongside Canaan Partners and Forbion. The proceeds fund porustobart, the Fc-enhanced CTLA-4 antibody Harbour BioMed licensed out for ex-Greater China rights in February 2026, which posted a 30% objective response rate in late-line MSS colorectal cancer.
Short sellers held the upper hand in HBM Holdings-B (02142.HK) on Sept. 9, pushing the stock down HK$0.390, or 2.701%, on the same day its partner company unveiled a US$225 million launch financing.
"We believe the greatest opportunity in oncology lies in treating disease earlier, in the neoadjuvant setting, when the tumor is still present, the immune system is still intact, and disease hasn't yet hardened its resistance to treatment," Caroline Loew, chief executive officer of Solstice Oncology, said.
The round was led by RA Capital Management, with Canaan Partners, Forbion and other investors participating. Solstice is advancing porustobart, a second-generation Fc-enhanced CTLA-4 antibody that Harbour BioMed discovered and licensed to the Boston-based company in February 2026 for development and commercialization outside Greater China. The molecule appears in Harbour BioMed's own pipeline as HBM4003.
The stock's decline came against HK$46.54 million in short selling, equal to 19.189% of turnover, according to AASTOCKS data as of the Sept. 9 close. That ratio is the crux of the story: a partner-level financing delivers no direct cash to Harbour BioMed, so the re-rating case rests entirely on how the market prices the de-risking of an asset the company no longer controls in its most valuable territories.
The clinical case is the substance behind the raise. In a Phase 2 study run by Harbour BioMed, porustobart combined with tislelizumab, a PD-1 inhibitor, produced a 30% objective response rate — 7 of 23 patients — in late-line microsatellite-stable metastatic colorectal cancer patients without liver metastases. Median duration of response was 8.4 months, and the safety profile supported later-stage development. Those patients had already failed prior therapy, which is why the number matters: MSS colorectal cancer has historically been unresponsive to immunotherapy, the segment with the largest share of colon cancer patients.
Solstice's Phase 2 trial will test porustobart with pembrolizumab in the neoadjuvant setting for clinical stage II-III MSS colon cancer, opening for enrollment early in the fourth quarter of 2026, with data expected in the second half of 2027. The company cleared an IND and moved directly into Phase 2 after being founded in February 2026.
Porustobart's design is the differentiator Solstice is selling. It works through two mechanisms — CTLA-4 checkpoint blockade and regulatory T cell depletion via antibody-dependent cellular cytotoxicity — and its heavy-chain-only structure gives it a half-life of four to five days, against roughly two to three weeks for first-generation CTLA-4 antibodies such as ipilimumab. A shorter half-life is intended to allow more flexible dosing and reduce the frequency and duration of immune-related adverse events, the main limitation of the first-generation class.
"Solstice brings together a compelling approach to treating patients with high unmet need in a potentially curative setting, a de-risked molecule that has already demonstrated activity in late-stage patients in Phase 1/2 studies, and a team with decades of drug development experience," Josh Resnick, a partner at RA Capital, said.
For Harbour BioMed shareholders, the arithmetic is indirect. The company retains an equity stake in Solstice and stands to collect milestones and royalties on ex-Greater China sales, but the US$225 million sits on Solstice's balance sheet, not Harbour BioMed's. What the round does is shift development funding for porustobart outside Greater China onto third-party capital, cutting Harbour BioMed's own cash burn on a program it would otherwise have to carry alone.
That is the argument for a re-rating, and the short sellers are not buying it yet. A 19.189% short ratio on a HK$12.89 billion market cap implies a meaningful cohort of traders positioned for the stock to give back gains rather than build on them. The next hard test is the Phase 2 readout in the second half of 2027; before that, enrollment progress from the fourth quarter of 2026 is the only scheduled checkpoint. Harbour BioMed's average trading volume of 5,819,360 shares means the short position can be covered quickly if sentiment turns, which cuts both ways.
Harbour BioMed's broader pipeline offers a second reference point for the stock. The company's HBM9378/WIN378, an ultra-long-acting TSLP antibody, reported positive Phase 2 results in asthma and has moved into Phase 3, and the shares were recently added to the Stock Connect eligible list — both developments that broaden the investor base beyond the porustobart story. Peer immuno-oncology names in Hong Kong have traded on pipeline news flow rather than near-term revenue, and Harbour BioMed's valuation now depends on whether investors treat the Solstice round as confirmation of the platform or as a transfer of upside to private holders.
This article is for informational purposes only and does not constitute investment advice.
